Lee DH, Linker R (2012)
Publication Type: Journal article
Publication year: 2012
Book Volume: 16
Pages Range: 451-62
Journal Issue: 5
DOI: 10.1517/14728222.2012.677438
INTRODUCTION: Myelin oligodendrocyte glycoprotein (MOG) is a myelin antigen at the outer surface of the central nervous system (CNS) myelin sheath, which may trigger T-cell as well as B-cell responses. It therefore constitutes a pivotal target for autoimmune responses, which result in inflammation and also demyelination in the CNS. In particular, it is a major target for auto-antibodies in experimental autoimmune encephalomyelitis (EAE), which mimics many aspects of multiple sclerosis (MS). B-cell responses toward MOG and anti-MOG antibodies have also been demonstrated in patients with demyelinating diseases, such as MS and acute disseminating encephalomyelitis (ADEM). Co-transfer of such anti-MOG antibodies in experimental models results in a distinct lesion pattern with antibody and complement-mediated demyelination, which is also hallmark of some lesion subtypes in MS. AREAS COVERED: A comprehensive literature search on MOG, B cells, MS, and ADEM was performed to outline the role of MOG in autoimmune demyelination in animal models and its relevance for human disease. EXPERT OPINION: Although the definite role of MOG in the pathogenesis of MS still remains to be clarified, innovative therapeutic strategies targeting B cells may reduce pathogenic immune responses against myelin auto-antigens including anti-myelin auto-antibodies.
APA:
Lee, D.-H., & Linker, R. (2012). The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy? Expert Opinion on Therapeutic Targets, 16(5), 451-62. https://doi.org/10.1517/14728222.2012.677438
MLA:
Lee, De-Hyung, and Ralf Linker. "The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?" Expert Opinion on Therapeutic Targets 16.5 (2012): 451-62.
BibTeX: Download